fMRI-Directed rTMS Targeting V1 Alleviates Depressive Symptoms in Young Individuals with Bipolar Disorder: Results from a Double-Blind Randomized Controlled Study - Summary - MDSpire
Advertisement
fMRI-Directed rTMS Targeting V1 Alleviates Depressive Symptoms in Young Individuals with Bipolar Disorder: Results from a Double-Blind Randomized Controlled Study
To evaluate the efficacy and explore the underlying neural mechanisms of fMRI-guided V1-targeted rTMS in adolescents and young adults with bipolar disorder depression (BD-D), with a focus on neural circuit modulation.
Key Findings:
High-frequency rTMS over V1 significantly reduced MADRS scores in the active group compared to sham, with p < 0.05.
Durability of effect was assessed at week 8, indicating sustained improvement in depressive symptoms.
Functional connectivity changes were observed in brain regions associated with emotional regulation, suggesting a potential mechanism of action.
Interpretation:
The study suggests that V1-targeted rTMS may provide a novel and effective intervention for alleviating depressive symptoms in young individuals with BD-D by modulating OFC-related circuits.
Limitations:
The study was limited to a specific age group and may not generalize to older populations, potentially affecting the applicability of results.
The reliance on a single medication (lurasidone) may affect the generalizability of findings to other treatment contexts.
Long-term effects beyond 8 weeks were not assessed, leaving questions about the sustainability of the treatment effects.
Conclusion:
fMRI-guided rTMS targeting V1 shows promise as a rapid and effective treatment for depressive symptoms in young individuals with bipolar disorder, warranting further research to confirm these findings and explore long-term outcomes.
